Literature DB >> 11702038

Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease.

C S Katsouras1, S A Karabina, A P Tambaki, J A Goudevenos, L K Michalis, L D Tsironis, C S Stroumbis, M S Elisaf, D A Sideris, A D Tselepis.   

Abstract

OBJECTIVE: The aim of this study was to investigate the possible associations between lipoprotein(a) [Lp(a)] concentrations or apolipoprotein(a) isoforms and the mode of clinical presentation of coronary heart disease (CHD) (acute thrombotic event or not).
METHODS: A total of 131 CHD patients and 71 age- and gender-matched individuals without known CAD (free of symptoms of heart disease) were enrolled in the study. CHD patients were classified into patients with a history of an acute coronary syndrome (ACS, n=94) and patients with stable angina (SA, n=37). Lp(a) levels were measured with an ELISA method, whereas apolipoprotein(a) isoform analysis was performed (in all patients and 33 controls) by electrophoresis in 1.5% SDS-agarose gels followed by immunoblotting. Isoform size was expressed as the number of kringle 4 (K4) repeats.
RESULTS: ACS patients had higher Lp(a) plasma levels 121.9 (0.8-84.1) mg/dl] and a greater proportion of elevated (> or = 30 mg/dl) Lp(a) concentrations (25.5%) compared with SA patients [9.2 (0.8-50.5) mg/dl, P < 0.01 and 10.8%, P < 0.05] and controls [8.0 (0.8-55.0) mg/dl, P < 0.01 and 11.2%, P < 0.05], while there were no differences between SA patients and controls. The median apolipoprotein(a)-isoform size was 26 K4. In 17 (10%) patients we could not detect any apolipoprotein(a) isoform bands by immunoblotting. ACS patients had a higher proportion of isoforms < 26 K4 (low molecular weight) than SA patients (56/85 vs. 12/33, P < 0.005) and controls (10/29, P < 0.005).
CONCLUSIONS: CAD patients with a history of ACS have higher Lp(a) plasma levels and a significantly higher proportion of low molecular weight apolipoprotein(a) isoforms compared with patients with SA or to controls.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11702038     DOI: 10.1177/174182670100800511

Source DB:  PubMed          Journal:  J Cardiovasc Risk        ISSN: 1350-6277


  6 in total

Review 1.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

2.  Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study.

Authors:  Stefania Lamon-Fava; Santica M Marcovina; John J Albers; Hal Kennedy; Carl Deluca; Charles C White; L Adrienne Cupples; Judith R McNamara; Leo J Seman; Vanina Bongard; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2011-04-07       Impact factor: 5.922

3.  Prevalence of thrombophilic disorders in takotsubo patients: the (ThROmbophylia in TAkotsubo cardiomyopathy) TROTA study.

Authors:  Emanuele Cecchi; Guido Parodi; Serena Fatucchi; Paola Angelotti; Cristina Giglioli; Anna Maria Gori; Brunella Bandinelli; Benedetta Bellandi; Elena Sticchi; Ilaria Romagnuolo; Lucia Mannini; David Antoniucci; Rosanna Abbate
Journal:  Clin Res Cardiol       Date:  2016-03-22       Impact factor: 5.460

4.  Assessing the severity of cardiovascular disease in 213 088 patients with coronary heart disease: a retrospective cohort study.

Authors:  Salwa S Zghebi; Mamas A Mamas; Darren M Ashcroft; Martin K Rutter; Harm VanMarwijk; Chris Salisbury; Christian D Mallen; Caroline A Chew-Graham; Nadeem Qureshi; Stephen F Weng; Tim Holt; Iain Buchan; Niels Peek; Sally Giles; David Reeves; Evangelos Kontopantelis
Journal:  Open Heart       Date:  2021-04

5.  Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects.

Authors:  Enzo Emanuele; Emmanouil Peros; Piercarlo Minoretti; Colomba Falcone; Angela D'Angelo; Lorenza Montagna; Diego Geroldi
Journal:  BMC Cardiovasc Disord       Date:  2003-12-12       Impact factor: 2.298

6.  Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells.

Authors:  Jin-Hyung Ahn; Hyun-Kyung Yu; Ho-Jeong Lee; Soon Won Hong; Sun Jin Kim; Jang-Seong Kim
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.